Product portfolio design risk
If products do not match customer needs or technology trends, customers may switch to alternatives
- Scope
- Genetic testing and transplant diagnostics portfolio
- Materiality
- high
Devyser Diagnostics
Devyser Diagnostics AB develops, manufactures and sells diagnostic solutions and analysis services for clinical genetics and transplant laboratories. Its portfolio is built around proprietary genetic testing products used for hereditary disease, oncology and transplant patient monitoring, with operations centered in Stockholm and sales in more than 65 countries.
| % | |
|---|---|
| Hereditary disease diagnostics | 40% Proprietary genetic tests used to diagnose inherited disorders and related conditions. |
| Transplant diagnostics | 30% Tests and workflows for donor matching, post-transplant follow-up and monitoring. |
| Oncology diagnostics | 15% Genetic testing solutions used to support targeted cancer treatment decisions. |
| Laboratory analysis services | 10% Support services and analysis offerings for clinical genetics laboratories. |
| Software and workflow solutions | 5% Data processing, analysis software and integrated laboratory workflow tools. |
Devyser sells primarily to clinical genetics laboratories and transplant laboratories that need reliable, fast and...
- Clinical genetics laboratoriesprimary
Buy genetic testing products and workflows to diagnose inherited diseases and improve lab throughput
- Transplant laboratoriesprimary
Buy transplant-related assays for donor matching and post-transplant monitoring
- Oncology-focused laboratoriessecondary
Use hereditary cancer and related assays to support treatment decisions
- Distributors and strategic partnerssecondary
Purchase or distribute products to extend reach in local markets and support customer service
- Research and reference laboratoriessecondary
Use products in validation, clinical studies and specialized diagnostic workflows
Devyser sells its products in more than 65 countries, with direct sales in selected markets and distributor-led sales...
- •Sales reach more than 65 countries worldwide
- •Direct sales are used in selected key markets
- •Distributor networks expand access in additional markets
- •Stockholm is the main production and R&D site
- •R&D also includes a team based in Italy
Devyser’s strategy centers on becoming a primary partner for clinical genetics laboratories through integrated...
01
Become a primary partner for clinical genetics laboratoriesmedium-term
Integrated workflows and support services increase customer stickiness and broaden the company’s role in the lab
02
Expand market access through partnerships and distributorsmedium-term
Channel partners accelerate penetration in new and existing markets without building full direct sales coverage everywhere
03
Optimize the product portfolioshort-term
Focusing resources on higher-potential assays improves product-market fit and supports scalable growth
04
Strengthen regulatory and IVDR readinessmedium-term
Regulatory approvals are essential for commercialization and broader market access
Devyser faces product, regulatory and market-access risks typical of diagnostics companies, including competition from...
Regulatory and market access risk
Products need approvals and reimbursement acceptance before launch in many countries
- Scope
- IVDR, FDA and MolDx pathways
- Materiality
- high
Competition from multinational diagnostics firms and home-brew tests
Customers can choose established brands or in-house laboratory methods
- Scope
- Clinical genetics and transplant labs
- Materiality
- high
Cybersecurity and data risk
Lab and company systems handle sensitive information and operational data
- Scope
- IT systems, clinical data and reporting
- Materiality
- medium
Future financing risk
If cash generation is insufficient, the company may need external capital to fund development
- Scope
- Product development and expansion plans
- Materiality
- high
Trade and tariff risk
International sourcing and freight can become more expensive or complex
- Scope
- Cross-border procurement and distribution
- Materiality
- medium
Revenue recognition timing
Channel and geography mix may shift quarterly revenue patterns
Development costs and capitalization judgments
Affects operating profit and intangible asset balances
Impairment of product-related assets
Could lead to write-downs if products underperform
Foreign exchange and financial instruments
Can move reported earnings and equity
: 11/08/2026